In a resource-constrained setting like Bangladesh, what proportion of a hospital's capacity is taken up with admissions for respiratory syncytial virus (RSV)? How many children needing admission are turned away every year because of lack of bed space? And how many of these "denials" and subsequent deaths might be prevented by the introduction of a maternal RSV vaccine or the monoclonal antibody nirsevimab?
Listen to Senjuti Saha, Deputy Executive Director of the Child Health Research Foundation, describe the results of her fascinating and potentially policy-changing study to our Editor-in-Chief, Zoë Mullan.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Lancet Group. Innehållet i podden är skapat av The Lancet Group och inte av,
eller tillsammans med, Poddtoppen.
